REAL-WORD CLINICAL CHARACTERIZATION OF METASTATIC HORMONE SENSITIVE PROSTATE CANCER: DATA FROM THE EUROPEAN NETWORK OF EXCELLENCE FOR BIG DATA IN PROSTATE CANCER (PIONEER)

被引：0
|
作者：
Nicoletti, Rossella
Rivas, Juan Gomez
Ibanez, Laura
Steinbeisserc, Carl
de Meulder, Bertrand
Golozar, Asieh
Axelsson, Susan Evans
Snijder, Robert
Bjartell, Anders
Cornford, Philip
Van Hemelrijck, Mieke
Beyer, Katharina
Willemse, Peter-Paul
Murtola, Teemu
Robool, Monique J.
Sierra, Jesus Moreno
Campi, Riccardo
Gacci, Mauro
Mottet, Nicolas
Merseburger, Axel
Ndow, James
机构：
来源：
JOURNAL OF UROLOGY | 2024年 / 211卷 / 05期
关键词：
D O I：
10.1097/01.JU.0001009428.69695.82.08
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
MP14-08
引用
收藏
页码：E222 / E222
页数：1
相关论文
共 50 条
  • [41] Leading from the front: Real-world treatment of metastatic hormone- sensitive prostate cancer in the Northwest of England
    Singh, A.
    Arif, Z.
    Birtle, A.
    CLINICAL ONCOLOGY, 2025, 38
  • [42] Real-world utilisation of upfront chemohormonal therapy in metastatic hormone-sensitive prostate cancer
    Kelly, R.
    Wong, S. S. L.
    Shapiro, J.
    Weickhardt, A. J.
    Parente, P.
    Azad, A.
    Uccellini, A.
    Torres, J.
    Parnis, F.
    Kwan, E.
    Brown, S.
    Steer, C.
    Warren, M.
    Gibbs, P.
    Anton, A.
    Tran, B.
    ANNALS OF ONCOLOGY, 2022, 33 : S1498 - S1499
  • [43] Real-world treatment of metastatic hormone-sensitive prostate cancer in the USA, Europe and Asia
    Goebell, Peter J.
    Raina, Rutika
    Chen, Stephanie
    Rege, Sanika
    Shah, Ruchit
    Grossman, Jamie Partridge
    Waldeck, A. Reginald
    FUTURE ONCOLOGY, 2024, 20 (14) : 903 - 918
  • [44] Osteoprotection in the management of metastatic prostate cancer: real-world data from Germany and decision guidance
    Hupe, Marie Christine
    Mueller, Marten
    Struck, Julian Peter
    Wiessmeyer, Judith Riccarda
    Ozimek, Tomasz
    Steuber, Thomas
    Gschwend, Jurgen
    Hammerer, Peter
    Kramer, Mario W.
    Merseburger, Axel S.
    AKTUELLE UROLOGIE, 2022, 53 (01) : 43 - 53
  • [45] CAN REAL-WORLD DATA REPLICATE RCT RESULTS? A RETROSPECTIVE COMPARATIVE EFFECTIVENESS STUDY OF DOCETAXEL IN METASTATIC HORMONE SENSITIVE PROSTATE CANCER USING GERMAN CLAIMS DATA
    Ghiani, M.
    Maywald, U.
    Wilke, T.
    Heeg, B.
    VALUE IN HEALTH, 2020, 23 : S424 - S424
  • [46] The optimal upfront therapy in metastatic hormone-sensitive prostate cancer: A network meta-analysis
    Mutlu, Hasan
    Bozcuk, Hakan
    JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2023, 19 (02) : 394 - 402
  • [47] Treatment of metastatic hormone-sensitive prostate cancer: from doublet therapy to triplet therapy
    Ye, Shi-jie
    Huang, Rui-da
    Fei, Xin
    Tao, Zhu-lei
    Liu, Wei-hua
    Ma, Qi
    POSTGRADUATE MEDICAL JOURNAL, 2024, 100 (1188) : 703 - 708
  • [48] Genomic profiles and clinical outcomes to distinguish primary from secondary metastatic hormone-sensitive prostate cancer (mHSPC).
    Nizialek, Emily
    Lim, Su Jin
    Wang, Hao
    Velho, Pedro Isaacsson
    Antonarakis, Emmanuel S.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [49] The Balancing Act: Assessing Treatment Burden Versus Treatment Benefit with Evolving Metastatic Hormone-sensitive Prostate Cancer Data
    Sweeney, Christopher J.
    Beltran, Himisha
    EUROPEAN UROLOGY, 2019, 76 (06) : 729 - 731
  • [50] Clinical outcomes in stratification subgroups in the ARASENS study in metastatic hormone-sensitive prostate cancer (mHSPC)
    Parnis, F.
    Tombal, B.
    Hussain, M.
    Saad, F.
    Fizazi, K.
    Sternberg, C. N.
    Crawford, E. D.
    Kopyltsov, E.
    Kalebasty, A. Rezazadeh
    Alekseev, B. Y.
    Montesa Pino, A.
    Ye, D.
    Melo Cruz, F. J. S.
    Tammela, T.
    Suzuki, H.
    Joensuu, H.
    Thiele, S.
    Li, R.
    Kuss, I.
    Smith, M.
    ANNALS OF ONCOLOGY, 2022, 33 : S1501 - S1502
12345